ChiCTR2000037255 版本V1.1 版本创建时间2020/10/11 17:08:39 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000037255 

最近更新日期:

Date of Last Refreshed on:

2020-10-11 17:03:30 

注册时间:

Date of Registration:

2020-08-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

杨文兰医师:请于伦理委员会批准后才开始征募参试者,并与我们联系上传伦理批件 心肺运动试验对低肺功能肺癌患者胸部手术风险的评估价值

Public title:

Evaluation of cardiopulmonary exercise test for chest surgery risk in lung cancer patients with low-level pulmonary function

注册题目简写:

English Acronym:

研究课题的正式科学名称:

心肺运动试验对低肺功能肺癌患者胸部手术风险的评估价值

Scientific title:

Evaluation of cardiopulmonary exercise test for chest surgery risk in lung cancer patients with low-level pulmonary function

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨文兰 

研究负责人:

郭健 

Applicant:

Yang Wen Lan 

Study leader:

Guo Jian 

申请注册联系人电话:

Applicant telephone:

+86 13818761522

研究负责人电话:

Study leader's
telephone:

+86 13761023718

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yangwenlan_2001@163.com

研究负责人电子邮件:

Study leader's E-mail:

jianjian11121987@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市杨浦区政民路507号

研究负责人通讯地址:

上海市杨浦区政民路507号

Applicant address:

507 Zhengmin Road, Yangpu District, Shanghai

Study leader's address:

507 Zhengmin Road, Yangpu District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市肺科医院

Applicant's institution:

Shanghai Pulmonary Hospital

研究负责人所在单位:

上海市肺科医院

Affiliation of the Leader:

Shanghai Pulmonary Hospital

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市肺科医院

Primary sponsor:

Shanghai Pulmonary Hospital

研究实施负责(组长)单位地址:

上海市杨浦区政民路507号

Primary sponsor's address:

507 Zhengmin Road, Yangpu District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市肺科医院

具体地址:

杨浦区政民路507号

Institution
hospital:

Shanghai Pulmonary Hospital

Address:

507 Zhengmin Road, Yangpu District

经费或物资来源:

上海市肺科医院临床研究基金

Source(s) of funding:

Clinical Research foundation of Shanghai Pulmonary Hospital

研究疾病:

肺癌  

Target disease:

Lung Cancer

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

本研究的目的是应用CPET对低肺功能肺癌患者进一步进行精准的术前风险评估及分层,同时评估术后3个月心肺功能、运动耐力的恢复情况。  

Objectives of Study:

The purpose of this study is to accurately assess the preoperative risk of lung cancer patients with low pulmonary function by using the CPET parameters, and to evaluate the recovery of cardiopulmonary function and exercise tolerance at 3 months after operation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1) 年龄≥40岁,男女不限;
2) 经组织学或细胞学证实的肺癌患者;
3) 既往未接受过以肺癌为适应症的系统性治疗或手术治疗;
4) 能够理解并依从指导说明,并能在体力上进行CPET;
5) 自愿参加临床研究,并签署知情同意书;
6) 行CPET筛查, 10ml/kg/min < PPO-VO2max ≤ 20 ml/kg/min的患者。

Inclusion criteria

1) Any age of male and female;
2) Lung cancer confirmed by histology or cytology;
3) No systematic treatment or surgical treatment with lung cancer as indication has been received in the past;
4) Be able to understand and follow instructions, and be able to perform CPET physically;
5) Volunteer to participate in clinical research and sign informed consent;
6) Patients with 10ml/kg / min

排除标准:

1) 排除不能配合或影响CPET分析结果的疾病:包括(但不限于)运动期间晕厥史;不稳定的缺血性心脏病、纽约心脏协会(NYHA)III/IV级左室衰竭、心律失常、未控制的高血压、脑血管疾病、神经-骨骼肌肉疾病、严重的代谢性疾病和精神性疾病,未经控制的甲状腺功能亢进、糖尿病、严重抑郁症、阿尔茨海默病;
2) 筛选之前4周内或筛选阶段,有呼吸道感染的患者。患者可在呼吸道感染恢复4周后再次筛选;
3) 过去5年内任何器官系统恶性肿瘤史;
4) 发生远处转移临床判断根据2019NCCN指南无法进行手术的患者。

Exclusion criteria:

1) Paients that cannot cooperate with or have diseases that affect the results of CPET analysis: including (but not limited to) the history of syncope during exercise; unstable ischemic heart disease, NYHA class III / IV left ventricular failure, arrhythmia, uncontrolled hypertension, cerebrovascular disease, neuroskeletal muscle disease, serious metabolic disease and mental disease, uncontrolled thyroid function Hyperactivity, diabetes, severe depression, Alzheimer's disease; 2) Patients with respiratory tract infection within 4 weeks before screening or at screening stage. Patients can be screened again 4 weeks after the recovery of respiratory infection;
3) Patients with history of malignancies in any organ system in the past 5 years;
4) Patients with distant metastasis who are unable to perform surgery according to NCCN guideline 2019.

研究实施时间:

Study execute time:

From 2020-10-01 00:00:00 To 2023-09-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-01 00:00:00 To 2022-06-01 00:00:00

干预措施:

Interventions:

组别:

A组

样本量:

79

Group:

Group A

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

组别:

B组

样本量:

79

Group:

Group B

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市肺科医院 

单位级别:

三甲 

Institution
hospital:

Shanghai Pulmonary Hospital

Level of the institution:

Teritary A

测量指标:

Outcomes:

指标中文名:

术后并发症

指标类型:

主要指标

Outcome:

Postoperative complications

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心肺运动试验

指标类型:

主要指标

Outcome:

Cardiopulmonary exercise test

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肺功能

指标类型:

主要指标

Outcome:

Pulmonary function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Borg 评分

指标类型:

主要指标

Outcome:

Borg score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血气分析

指标类型:

主要指标

Outcome:

Arterial blood gas

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

袁平应用计算机程序随机化

Randomization Procedure (please state who generates the random number sequence and by what method):

Yuan Ping randomly enrolled patients using computer program

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

公开原始数据日期大概于2022年12月左右,将在中国临床试验注册中心登记

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The original data will be published around December 2022 and will be registered in China clinical trial registration center

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理采用“病例记录表“和“电子采集和管理系统”

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management adopts"Case Record Form, CRF"and"Electronic Data Capture, EDC"

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-08-27 11:45:54